Abstract
Background
The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke. In the present analysis we wanted to see if the effects of blood pressure lowering are harmful in the subgroup of patients with carotid artery stenosis.
Methods
SCAST was a randomized- and placebo-controlled, double-masked trial of 2029 patients with acute stroke and high systolic blood pressure (≥140 mmHg). Of 1733 patients with ischemic stroke 993 underwent carotid artery imaging, and the degree of stenosis was categorized as no/insignificant (0–49%,
Results
Among patients with moderate or severe carotid artery stenosis the vascular end-point occurred in 9 of 87 patients (10·3%) treated with candesartan and in 17 of 100 controls (17·0%), and there was no evidence of a different risk in patients with severe stenosis (adjusted hazard ratio 0·74, 95% confidence interval 0·28–1·96,
Conclusions
There is no clear evidence that the effect of candesartan is qualitatively different in patients with carotid artery stenosis, but there are signals that patients with severe stenosis are at particularly high risk of stroke progression and poor functional outcome.
Get full access to this article
View all access options for this article.
